Premium
Effect of Hashimoto thyroiditis on low‐dose radioactive‐iodine remnant ablation
Author(s) -
Kwon Hyungju,
Choi June Young,
Moon Jae Hoon,
Park Hyo Jin,
Lee Won Woo,
Lee Kyu Eun
Publication year - 2016
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.24080
Subject(s) - medicine , iodine , radioactive iodine , ablation , thyroid carcinoma , thyroid , thyroiditis , nuclear medicine , gastroenterology , urology , chemistry , organic chemistry
Background Radioactive‐iodine remnant ablation is an integral part of the papillary thyroid carcinoma (PTC) treatment. Although a minimum dose is usually recommended, there is controversy as to whether the low‐dose (1100 MBq) radioactive‐iodine remnant ablation is adequate for selected patients. Methods A retrospective cohort study was conducted on 691 patients. Patients with no remnant thyroid on the follow‐up whole body scan and low stimulated thyroglobulin (sTg) level (<2.0 ng/mL) were deemed as successful treatment cases. Results Initial low‐dose radioactive‐iodine remnant ablation was successful in 431 patients (62.3%). Multivariate analysis demonstrated a negative correlation between successful radioactive‐iodine remnant ablation and coexisting Hashimoto thyroiditis based on histopathology diagnosis (odds ratio [OR] = 3.23; p < .001) as well as elevated preablation sTg (OR = 1.24; p < .001). Conclusion Our data suggest that coexisting Hashimoto thyroiditis and elevated sTg are negative predictive factors for successful low‐dose radioactive‐iodine remnant ablation treatment. An appropriate risk‐adjusted approach may improve the efficacy of radioactive‐iodine remnant ablation treatment. © 2015 Wiley Periodicals, Inc. Head Neck 38 : E730–E735, 2016